iShares
®
Neuroscience
and
Healthcare
ETF
Schedule
of
Investments
(unaudited)
April
30,
2026
(Percentages
shown
are
based
on
Net
Assets)
1
Schedule
of
Investments
Security
Shares
Value
a
Common
Stocks
Biotechnology
 — 73.2%
AC
Immune
SA
(a)
.........................
3,350
$
10,151
ACADIA
Pharmaceuticals,
Inc.
(a)
...............
8,328
186,964
Acumen
Pharmaceuticals,
Inc.
(a)
...............
2,555
6,106
Alector,
Inc.
(a)
...........................
4,108
9,736
Alkermes
PLC
(a)
..........................
6,446
217,295
Anavex
Life
Sciences
Corp.
(a)
.................
4,943
16,510
Annexon,
Inc.
(a)(b)
.........................
7,048
41,372
Argenx
SE,
ADR
(a)
........................
257
200,902
Arrowhead
Pharmaceuticals,
Inc.
(a)
.............
3,103
228,008
Benitec
Biopharma,
Inc.
(a)(b)
..................
1,798
21,666
BioArctic
AB,
Class
B
(a)(c)
....................
2,026
71,053
Biogen,
Inc.
(a)
...........................
1,004
190,037
Biohaven
Ltd.
(a)
..........................
7,016
67,283
Bright
Minds
Biosciences,
Inc.
(a)(b)
..............
539
47,405
Capricor
Therapeutics,
Inc.
(a)
.................
2,693
90,431
Catalyst
Pharmaceuticals,
Inc.
(a)
...............
6,048
170,130
Centessa
Pharmaceuticals
PLC,
ADR
(a)
..........
5,186
204,432
Denali
Therapeutics,
Inc.
(a)
..................
7,800
146,016
Design
Therapeutics,
Inc.
(a)(b)
.................
1,744
23,718
Dianthus
Therapeutics,
Inc.
(a)
.................
1,998
175,424
Dyne
Therapeutics,
Inc.
(a)
...................
6,966
122,253
Entrada
Therapeutics,
Inc.
(a)
.................
1,178
15,903
Gain
Therapeutics,
Inc.
(a)
....................
2,048
3,871
Idorsia
Ltd.
(a)(b)
...........................
9,565
45,098
Inhibikase
Therapeutics,
Inc.
(a)
................
5,080
9,601
Larimar
Therapeutics,
Inc.
(a)(b)
.................
2,281
9,261
MapLight
Therapeutics,
Inc.
(a)(b)
...............
677
21,576
Neurocrine
Biosciences,
Inc.
(a)
................
1,448
190,658
Neurogene,
Inc.
(a)
.........................
678
17,689
Oncolys
BioPharma,
Inc.
(a)
...................
1,400
25,402
Ovid
Therapeutics,
Inc.
(a)
....................
6,364
17,628
PepGen,
Inc.
(a)
..........................
3,356
5,504
Praxis
Precision
Medicines,
Inc.
(a)
..............
594
189,385
Prothena
Corp.
PLC
(a)
......................
2,392
26,456
PTC
Therapeutics,
Inc.
(a)
....................
2,938
191,146
REGENXBIO,
Inc.
(a)
.......................
2,532
22,712
SanBio
Co.
Ltd.
(a)
.........................
3,200
38,842
Sangamo
Therapeutics,
Inc.
(a)(b)
...............
21,725
2,590
Santhera
Pharmaceuticals
Holding
AG
(a)
.........
656
14,291
Sarepta
Therapeutics,
Inc.
(a)
.................
5,480
114,422
Scholar
Rock
Holding
Corp.
(a)
................
4,075
189,936
Solid
Biosciences,
Inc.
(a)
....................
3,302
23,973
Taysha
Gene
Therapies,
Inc.
(a)(b)
...............
12,369
79,038
Tonix
Pharmaceuticals
Holding
Corp.
(a)
..........
688
8,896
Vanda
Pharmaceuticals,
Inc.
(a)
................
2,996
21,272
Voyager
Therapeutics,
Inc.
(a)
.................
2,514
9,377
Xenon
Pharmaceuticals,
Inc.
(a)
................
4,419
247,641
3,789,060
a
Health
Care
Equipment
&
Supplies
 — 6.4%
Axogen,
Inc.
(a)
...........................
2,800
120,960
Brainsway
Ltd.,
ADR
(a)
.....................
1,869
30,951
Ceribell,
Inc.
(a)
...........................
1,337
26,954
ClearPoint
Neuro,
Inc.
(a)(b)
...................
1,418
15,853
Integra
LifeSciences
Holdings
Corp.
(a)
...........
3,675
38,735
MicroPort
NeuroScientific
Corp.
(b)
..............
18,000
23,965
NeuroPace,
Inc.
(a)
........................
1,398
23,570
Peijia
Medical
Ltd.
(a)(c)
......................
26,000
20,679
Zylox-Tonbridge
Medical
Technology
Co.
Ltd.,
Class
H
(c)
9,000
26,359
328,026
a
Security
Shares
Value
a
Health
Care
Technology
 — 0.1%
BrainAurora
Medical
Technology
Ltd.
(a)
..........
10,000
$
4,839
a
Pharmaceuticals
 — 19.3%
Alto
Neuroscience,
Inc.
(a)
....................
1,571
40,312
Axsome
Therapeutics,
Inc.
(a)
.................
1,144
237,666
Cognition
Therapeutics,
Inc.
(a)
................
4,343
5,472
Edgewise
Therapeutics,
Inc.
(a)(b)
...............
4,232
131,023
Filana
Therapeutics,
Inc.
(a)
...................
2,457
3,563
H
Lundbeck
A.S.
.........................
14,762
99,239
LB
Pharmaceuticals,
Inc.
(a)
..................
1,036
32,851
Medincell
SA,
NVS
(a)(b)
.....................
1,155
33,455
Myung
In
Pharma
Co.
Ltd.
...................
211
8,041
Neumora
Therapeutics,
Inc.
(a)
.................
3,060
7,558
Neuren
Pharmaceuticals
Ltd.
(a)
................
6,016
54,701
Newron
Pharmaceuticals
SpA
(a)
...............
991
18,137
Rapport
Therapeutics,
Inc.
(a)
.................
1,610
53,339
Relmada
Therapeutics,
Inc.
(a)
.................
3,334
25,072
SK
Biopharmaceuticals
Co.
Ltd.
(a)
..............
1,547
105,634
Supernus
Pharmaceuticals,
Inc.
(a)
..............
3,000
144,000
1,000,063
a
Technology
Hardware,
Storage
&
Peripherals
 — 0.9%
Dynavox
Group
AB
(a)
......................
5,451
48,446
a
a
Total
Long-Term
Investments — 99.9%
(Cost:
$3,648,200)
..................................
5,170,434
a
Short-Term
Securities
Money
Market
Funds
 — 
9.3%
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares,
3.83%
(d)(e)(f)
......................
476,827
476,970
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares,
3.61%
(d)(e)
............................
2,445
2,445
a
Total
Short-Term
Securities — 9.3%
(Cost:
$479,376)
...................................
479,415
Total
Investments
—
109.2%
(Cost:
$4,127,576)
..................................
5,649,849
Liabilities
in
Excess
of
Other
Assets
—
(9.2)%
...............
(475,413)
Net
Assets
—
100.0%
.................................
$
5,174,436
(a)
Non-income
producing
security.
(b)
All
or
a
portion
of
this
security
is
on
loan.
(c)
Security
exempt
from
registration
pursuant
to
Rule
144A
under
the
Securities
Act
of
1933,
as
amended.
These
securities
may
be
resold
in
transactions
exempt
from
registration
to
qualified
institutional
investors.
(d)
Affiliate
of
the
Fund.
(e)
Annualized
7-day
yield
as
of
period
end.
(f)
All
or
a
portion
of
this
security
was
purchased
with
the
cash
collateral
from
loaned
securities.
Schedule
of
Investments
(unaudited)
(continued)
April
30,
2026
iShares
®
Neuroscience
and
Healthcare
ETF
2
Fair
Value
Hierarchy
as
of
Period
End
Various
inputs
are
used
in
determining
the
fair
value
of
financial
instruments
at
the
measurement
date.
These
inputs
to
valuation
techniques
are
categorized
into
a
fair
value
hierarchy
consisting
of
three
broad
levels
for
financial
reporting
purposes
as
follows:
Level
1
–
Unadjusted
price
quotations
in
active
markets/exchanges
that
the
Fund
has
the
ability
to
access
for
identical
assets
or
liabilities;
Level
2
–
Inputs
other
than
quoted
prices
included
within
Level
1
that
are
observable
for
the
asset
or
liability,
either
directly
or
indirectly;
and
Level
3
–
Inputs
that
are
unobservable
and
significant
to
the
entire
fair
value
measurement
for
the
asset
or
liability
(including
the
Valuation
Committee’s
assumptions
used
in
determining
the
fair
value
of
financial
instruments).
The
hierarchy
gives
the
highest
priority
to
unadjusted
quoted
prices
in
active
markets
for
identical
assets
or
liabilities
(Level
1
measurements)
and
the
lowest
priority
to
unobservable
inputs
(Level
3
measurements).
Accordingly,
the
degree
of
judgment
exercised
in
determining
fair
value
is
greatest
for
instruments
categorized
in
Level
3.
The
inputs
used
to
measure
fair
value
may
fall
into
different
levels
of
the
fair
value
hierarchy.
In
such
cases,
for
disclosure
purposes,
the
fair
value
hierarchy
classification
is
determined
based
on
the
lowest
level
input
that
is
significant
to
the
fair
value
measurement
in
its
entirety.
Investments
classified
within
Level
3
have
significant
unobservable
inputs
used
by
the
Valuation
Committee
in
determining
the
price
for
Fair
Valued
Investments.
Level
3
investments
include
equity
or
debt
issued
by
privately
held
companies
or
funds
that may
not have
a
secondary
market
and/or may
have a
limited
number
of
investors.
The
categorization
of
a
value
determined
for
financial
instruments
is
based
on
the
pricing
transparency
of
the
financial
instruments
and
is
not
necessarily
an
indication
of
the
risks
associated
with
investing
in
those
securities.
For
information
about
the
Fund’s
policy
regarding
valuation
of
financial
instruments,
refer
to
its
most
recent
financial
statements.
The
following
table
summarizes
the
Fund’s
financial
instruments
categorized
in
the
fair
value
hierarchy.
The
breakdown
of
the
Fund’s
financial
instruments
into
major
categories
is
disclosed
in
the
Schedule
of
Investments
above. 
Affiliates
Investments
in
issuers
considered
to
be
affiliate(s)
of
the
Fund
during
the
period
ended
April
30,
2026
for
purposes
of
Section
2(a)(3)
of
the
Investment
Company
Act
of
1940,
as
amended,
were
as
follows:
Affiliated
Issuer
Value
at
07/31/25
Purchases
at
Cost
Proceeds
from
Sale
s
Net
Realized
Gain
(Loss)
Change
in
Unrealized
Appreciation
(Depreciation)
Value
at
04/30/26
  Shares
Held
at
04/30/26
Income
  Capital
Gain
Distributions
from
Underlying
Funds
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
$
1,146,198
‌
$
—
‌
$
(669,253
)
(a)
$
21
‌
$
4
‌
$
476,970
‌
476,827
‌
$
5,501
(b)
$
—
‌
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
—
‌
2,445
(a)
—
‌
—
‌
—
‌
2,445
‌
2,445
‌
57
‌
—
‌
$
—
‌
$
21
‌
$
4
‌
$
479,415
‌
$
5,558
‌
$
—
‌
(a)
Represents
net
amount
purchased
(sold).
(b)
All
or
a
portion
represents
securities
lending
income
earned
from
the
reinvestment
of
cash
collateral
from
loaned
securities,
net
of
collateral
investment
fees,
and
other
payments
to
and
from
borrowers
of
securities.
Level
1
Level
2
Level
3
Total
Assets
Investments
Long-Term
Investments
Common
Stocks
.........................................
$
4,731,194
‌
$
439,240
‌
$
—
‌
$
5,170,434
‌
Short-Term
Securities
Money
Market
Funds
......................................
479,415
‌
—
‌
—
‌
479,415
‌
$
5,210,609
‌
$
439,240
‌
$
—
‌
$
5,649,849
‌
Portfolio
Abbreviation
ADR
American
Depositary
Receipt
NVS
Non-Voting
Shares